Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Matthay

Showing results (261-270 of 316) with videos related to

Pageof 32
Sort By:
Medical and Pediatric Oncology|July 24, 2001
Loss of heterozygosity for chromosome 14q in neuroblastomaP M Thompson, B A Seifried, S K Kyemba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force reportSusan L Cohn, Andrew D J Pearson, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force reportTom Monclair, Garrett M Brodeur, Peter F Ambros, et al.
Pediatric Blood & Cancer|June 15, 2011
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) studyHeidi V Russell, Susan G Groshen, Tasnim Ara, et al.
The New England Journal of Medicine|November 25, 2005
Chromosome 1p and 11q deletions and outcome in neuroblastomaEdward F Attiyeh, Wendy B London, Yael P Mossé, et al.
International Journal of Radiation Oncology, Biology, Physics|December 16, 2022
Modulation of Radiation Biomarkers in a Randomized Phase II Study of <sup>131</sup>I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory NeuroblastomaKevin Campbell, Susan Groshen, Angela C Evans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group studyJ M Maris, M J Weiss, C Guo, et al.
Pediatric Blood & Cancer|July 2, 2013
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortiumBarry J Maurer, Min H Kang, Judith G Villablanca, et al.
Pediatric Blood & Cancer|May 18, 2023
Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology GroupKeri A Streby, Marguerite T Parisi, Barry L Shulkin, et al.
Cancer|September 14, 2022
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Judith G Villablanca, Barbara Hero, et al.
Pageof 32

Showing results (261-270 of 316) with videos related to

Sort By:
Pageof 32
Medical and Pediatric Oncology|July 24, 2001
Loss of heterozygosity for chromosome 14q in neuroblastomaP M Thompson, B A Seifried, S K Kyemba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force reportSusan L Cohn, Andrew D J Pearson, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force reportTom Monclair, Garrett M Brodeur, Peter F Ambros, et al.
Pediatric Blood & Cancer|June 15, 2011
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) studyHeidi V Russell, Susan G Groshen, Tasnim Ara, et al.
The New England Journal of Medicine|November 25, 2005
Chromosome 1p and 11q deletions and outcome in neuroblastomaEdward F Attiyeh, Wendy B London, Yael P Mossé, et al.
International Journal of Radiation Oncology, Biology, Physics|December 16, 2022
Modulation of Radiation Biomarkers in a Randomized Phase II Study of <sup>131</sup>I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory NeuroblastomaKevin Campbell, Susan Groshen, Angela C Evans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group studyJ M Maris, M J Weiss, C Guo, et al.
Pediatric Blood & Cancer|July 2, 2013
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortiumBarry J Maurer, Min H Kang, Judith G Villablanca, et al.
Pediatric Blood & Cancer|May 18, 2023
Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology GroupKeri A Streby, Marguerite T Parisi, Barry L Shulkin, et al.
Cancer|September 14, 2022
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Judith G Villablanca, Barbara Hero, et al.
Pageof 32